Bass Gets PTAB Review Of Fresenius Diprivan Patent

By Matthew Bultman (June 9, 2016, 2:44 PM EDT) -- Hedge fund manager Kyle Bass has convinced the Patent Trial and Appeal Board to review a patent covering Fresenius' anesthetic agent Diprivan, while the board said Wednesday it was fine that Bass' group, the Coalition for Affordable Drugs, wasn't included in the case....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!